| Literature DB >> 6678859 |
R B Vance, W A Knight, T T Chen, J J Costanzi, A F LoBuglio.
Abstract
One hundred and eight patients with non-small cell lung cancer were treated in a Phase II trial with MGBG at a dose of 600 mg/m2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 1/40 with squamous cell carcinoma. No responses were noted in 24 patients with large cell carcinoma. Overall, the drug was reasonably well-tolerated. At this dosage and schedule, MGBG has no substantial antitumor activity for patients with non-small cell lung cancer.Entities:
Mesh：
Substances：
Year: 1983 PMID： 6678859 DOI： 10.1007/bf00180196
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850